ML-23 The outcome of malignant lymphoma of the central nervous system in a single institution

Background: Although high dose-methotrexate therapy has been performed for primary central nervous system malignant lymphoma (PCNSL), R-MPV (rituximab, methotrexate (MTX), procarbazine and vincristine) therapy is currently the first line therapy for (PCNSL) in our hospital. This study examines the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuwahara, Kiyonori, Ohba, Shigeo, Matsumura, Kazuyasu, Higashiguchi, Saeko, Kojima, Daijiro, Muto, Jun, Nakae, Shunsuke, Nishiyama, Yuya, Yamada, Seiji, Adachi, Kazuhide, Abe, Masato, Hasegawa, Mitsuhiro, Hirose, Yuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699112/
http://dx.doi.org/10.1093/noajnl/vdaa143.079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699112/
http://dx.doi.org/10.1093/noajnl/vdaa143.079

Ejemplares similares